UNSPSC 51287008: Solasulfone

This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H12JE4313S. European Medicines Agency schedules Solasulfone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10575MIG. Solasulfone generally arises in the molecular formula C30H28N2NA4O14S5. The term SOLASULFONE is an International Non-Proprietary Name or INN. SOLASULFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

SMILES: S(=O)(=O)(O)C(CC(S(=O)(=O)O)NC1CCC(S(=O)(=O)C2CCC(NC(S(=O)(=O)O)CC(S(=O)(=O)O)C3CCCCC3)CC2)CC1)C1CCCCC1.[NA].[NA].[NA].[NA].

UNSPSC 51287008 Solasulfone, a Commodity code, does not map accurately to the recent state and local procurement activity tagged under it. The four opportunities posted between January and June 2026 span naloxone procurement, direct-to-manufacturer pharmacy programs, fire department medical and first aid supplies, and cooperative purchasing of generic pharmaceuticals and OTC products—none of which involve solasulfone, a specialty chemical reagent used in laboratory and analytical applications. The mismatch suggests either miscoding at the time of opportunity posting or a fundamental disconnect between the code's nominal scope and current buying patterns in this category.

The geographic distribution of these unrelated opportunities spans Florida (Seminole County), Texas (HHS Commission), Florida (City of Tampa), and a multi-state cooperative anchored in Minnesota (MMCAP, including Oregon members). Recent solicitation activity includes an IFB from Seminole County for naloxone and drug deactivation systems (due July 26, 2023, though posted June 30, 2026); an RFI from the Texas HHS Commission on direct-to-manufacturer pharmacy programs (April 3, 2026); an IFB from the City of Tampa for medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 and SLBE set-asides (due March 13, 2026); and an RFP from MMCAP for generic pharmaceuticals and OTC products across multiple state and local jurisdictions (due March 26, 2026). The code shows no relevant recent activity for solasulfone itself; prospectors in chemical or analytical-supply markets should verify coding with issuing bodies before pursuing opportunities tagged to this category.